Protagonist Therapeutics Announces Removal of FDA Clinical Hold on the Rusfertide Clinical Development ProgramPRNewsWire • 10/11/21
Protagonist Therapeutics Announces Data from Phase 2 Rusfertide Study in Hereditary Hemochromatosis Selected for Oral Presentation at the Annual AASLD MeetingPRNewsWire • 10/04/21
PROTAGONIST ALERT: Bragar Eagel & Squire, P.C. is Investigating Protagonist on Behalf of Protagonist Stockholders and Encourages Investors to Contact the FirmBusiness Wire • 09/23/21
Protagonist Therapeutics (PTGX) Moves 18.2% Higher: Will This Strength Last?Zacks Investment Research • 09/22/21
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Protagonist Therapeutics, Inc. - PTGXNewsfile Corp • 09/21/21
Protagonist Therapeutics Reports FDA Clinical Hold on Rusfertide Clinical Development ProgramPRNewsWire • 09/17/21
Protagonist Therapeutics Appoints Scott Plevy, M.D., Executive Vice President and Therapeutic Head, GastroenterologyPRNewsWire • 09/07/21
Protagonist Therapeutics Announces Resolution of Contract Dispute with Zealand PharmaPRNewsWire • 08/10/21
Protagonist Therapeutics (PTGX) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/04/21
Protagonist Therapeutics Reports Second Quarter 2021 Financial Results and Recent Company ProgressPRNewsWire • 08/04/21
Will Protagonist Therapeutics (PTGX) Report Negative Q2 Earnings? What You Should KnowZacks Investment Research • 07/29/21
Protagonist Therapeutics Announces Amendment of Agreement with Janssen Biotech for the Continued Development and Commercialization of IL-23 AntagonistsPRNewsWire • 07/28/21
Protagonist Therapeutics, Inc. Announces Closing of $132.2 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional SharesPRNewsWire • 06/18/21
Protagonist Therapeutics (PTGX) Stock Jumps 9.3%: Will It Continue to Soar?Zacks Investment Research • 06/17/21
Protagonist Therapeutics Announces Pricing of $115 Million Upsized Public Offering of Common StockPRNewsWire • 06/16/21
Protagonist Stock Moves Higher As Rusfertide Shows Durability Of Effect, Symptom Improvements In Blood Cancer TrialBenzinga • 06/11/21
Protagonist Therapeutics Announces Updated Phase 2 Data Supporting Long-Term Efficacy of Rusfertide in Polycythemia VeraPRNewsWire • 06/11/21